Overview

An Open Study of Tipepidine Hibenzate in Adolescent Patients With Depression

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Accumulating evidence suggests a role of G protein-coupled inwardly-rectifying potassium (GIRK) channel in the pathology of excitement of nerve, and the medicine with the action (like the Tipepidine Hibenzate) is expected as a new curative medicine of adolescent depression. The purpose of this research is to confirm the effect by carrying out the additional dosage of the Tipepidine Hibenzate to the adolescent patients with depression. If suggestion is obtained by this research about the effect on adolescent patients with depression of Tipepidine Hibenzate, it can contribute to development of the medical treatment of adolescent patients with depression.
Phase:
Phase 2
Details
Lead Sponsor:
Chiba University